The Spectrum of Histomorphological Changes and Pathological Tumor Response following Preoperative Oral Metronomic Chemotherapy in Oral Squamous Cell Carcinoma

Abstract

Sithara Aravind

Background Oral metronomic chemotherapy (OMCT) represents an emerging concept in cancer treatment involving frequent administration of chemotherapeutic drugs at doses below maximum tolerated doses and with no prolonged drug-free break. OMCT is being tried preoperatively in developing nations with constrained resources to prevent disease progression during the waiting period from diagnosis to surgery (bridge OMCT). The aim of the present study was to assess the spectrum of histomorphological changes and pathological tumor response following bridge OMCT in oral squamous cell carcinoma (OSCC) and to propose a new pathological response scoring system.

Materials and Methods A retrospective single-center study comprised of tissue sections of tumor proper and metastatic lymph nodes of 50, locally advanced OSCC patients treated with bridge OMCT, and had completed definitive surgery were analyzed. The present study evaluated the histomorphological features and proposed a new scoring system for pathologic tumor response. The pathologic tumor response was categorized as complete response (pCR), no response (pNR), and partial response (pPR).

Results Of the total 50 patients, 2 patients had pCR, 3 had pNR, and 45 patients had pPR as per the new proposed scoring system. Note that 96% of the cases showed no disease progression.

Conclusion Bridge OMCT is a novel treatment method that can be used to tide over the waiting period between the diagnosis and surgery in resource-constrained institutions with heavy patient load. This mode of treatment in locally advanced OSCC seems to provide promising results in this setting. Large multicentric trials are warranted to confirm these results.

Keywords

histomorphological changes - oral metronomic chemotherapy - oral squamous cell carcinoma - pathologic tumor response

Publikationsverlauf

Artikel online veröffentlicht:
02. Februar 2022

• References

• 1 Bahl A, Bakhshi S. Metronomic chemotherapy in progressive pediatric malignancies: old drugs in new package. Indian J Pediatr 2012; 79 (12) 1617-1622
• 2 Maiti R. Metronomic chemotherapy. J Pharmacol Pharmacother 2014; 5 (03) 186-192
• 3 De Felice F, Musio D, Tombolini V. Head and neck cancer: metronomic chemotherapy. BMC Cancer 2015; 15: 677
• 4 Sethi D, Sen R, Parshad S, Khetarpal S, Garg M, Sen J. Histopathologic changes following neoadjuvant chemotherapy in various malignancies. Int J Appl Basic Med Res 2012; 2 (02) 111-116
• 5 Hirakawa H, Hanai N, Suzuki H. et al. Prognostic importance of pathological response to neoadjuvant chemotherapy followed by definitive surgery in advanced oral squamous cell carcinoma. Jpn J Clin Oncol 2017; 47 (11) 1038-1046
• 6 Hirakawa H, Hanai N, Ozawa T. et al. Prognostic impact of pathological response to neoadjuvant chemotherapy followed by definitive surgery in sinonasal squamous cell carcinoma. Head Neck 2016; 38 (Suppl. 01) E1305-E1311
• 7 Pai PS, Vaidya AD, Prabhash K, Banavali SD. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous cell cancers: a matched-pair analysis. Indian J Cancer 2013; 50 (02) 135-141
• 8 Shin DM, Zhang H, Saba NF. et al. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res 2013; 19 (05) 1244-1256
• 9 Patil VM, Chakraborty S, Jithin TK. et al. An audit of the results of a triplet metronomic chemotherapy regimen incorporating a tyrosine kinase inhibitor in recurrent/metastatic head and neck cancers patients. South Asian J Cancer 2016; 5 (02) 48-51
• 10 Brandwein-Gensler M, Teixeira MS, Lewis CM. et al. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol 2005; 29 (02) 167-178
• 11 Braun OM, Neumeister B, Popp W. et al. Histologic tumor regression grades in squamous cell carcinoma of the head and neck after preoperative radiochemotherapy. Cancer 1989; 63 (06) 1097-1100
• 12 Mandard AM, Dalibard F, Mandard JC. et al. Pathological assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680-2686
• 13 O'Neil M, Damjanov I. Histopathology of colorectal cancer after neoadjuvant chemoradiation therapy. Open Pathol J 2009; 3: 91-98
• 14 Chakrabarti S, Mandal PK, Chowdhury AR, Das S. Consequence of neo-adjuvant chemotherapy on morphology of breast carcinoma: a systematic evaluation. Indian J Cancer 2016; 53 (01) 29-33
• 15 McCluggage WG, Lyness RW, Atkinson RJ. et al. Morphological effects of chemotherapy on ovarian carcinoma. J Clin Pathol 2002; 55 (01) 27-31
• 16 Wedemeyer I, Kreppel M, Scheer M, Zöller JE, Büttner R, Drebber U. . Histopathological assessment of tumour regression, nodalstage and status of resection margins determines prognosis in patients with oral squamous cell carcinoma treated with neoadjuvant radiochemotherapy. Oral Dis 2014; 20: e81-e89
• 17 Simsek C, Esin E, Yalcin S. Metronomic chemotherapy: a systematic review of the literature and clinical experience. J Oncol 2019; 2019: 5483791
• 18 Marçola M, Rodrigues CE. Endothelial progenitor cells in tumor angiogenesis: another brick in the wall. Stem Cells Int 2015; 2015 (02) 832649
• 19 Mpekris F, Baish JW, Stylianopoulos T, Jain RK. Role of vascular normalization in benefit from metronomic chemotherapy. Proc Natl Acad Sci U S A 2017; 114 (08) 1994-1999
• 20 Norrby K. Metronomic chemotherapy and anti-angiogenesis: can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth?. APMIS 2014; 122 (07) 565-579
• 21 Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 2002; 192 (01) 1-15
• 22 Ghiringhelli F, Menard C, Puig PE. et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56 (05) 641-648